ProQR Therapeutics (PRQR) News Today $2.63 +0.04 (+1.54%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period JMP Securities Reiterates Market Outperform Rating for ProQR Therapeutics (NASDAQ:PRQR)December 15, 2024 | americanbankingnews.comProQR Therapeutics' (PRQR) "Buy" Rating Reiterated at HC WainwrightDecember 15, 2024 | americanbankingnews.comBrokerages Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $7.60December 15, 2024 | americanbankingnews.comChardan Capital Reiterates "Buy" Rating for ProQR Therapeutics (NASDAQ:PRQR)December 14, 2024 | americanbankingnews.comJMP Securities Reiterates "Market Outperform" Rating for ProQR Therapeutics (NASDAQ:PRQR)JMP Securities restated a "market outperform" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday.December 12, 2024 | marketbeat.comProQR Therapeutics' (PRQR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of ProQR Therapeutics in a research report on Thursday.December 12, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Given Buy Rating at Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Thursday.December 12, 2024 | marketbeat.comProQR’s Promising RNA-Editing Advancements and Strategic Collaborations Drive Buy RatingDecember 12, 2024 | markets.businessinsider.comProQR Therapeutics announces $8.1M in new funding from RSRTDecember 12, 2024 | markets.businessinsider.comProQR Therapeutics Advances Axiomer RNA-Editing Platform with Strategic PartnershipsDecember 11, 2024 | tipranks.comProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing CollaborationDecember 11, 2024 | markets.businessinsider.comProQR Therapeutics appoints Beal as Chief ADAR ScientistDecember 10, 2024 | tipranks.comProQR Appoints Peter A. Beal, PhD, as Chief ADAR ScientistDecember 10, 2024 | globenewswire.comProQR Therapeutics price target raised to $8 from $5 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comProQR Highlights RNA Innovations in Upcoming EventDecember 5, 2024 | tipranks.comProQR Therapeutics Highlights Q3 2024 Financial ResultsNovember 21, 2024 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Time to Sell?ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?November 21, 2024 | marketbeat.comWhat is Chardan Capital's Forecast for PRQR FY2024 Earnings?ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Chardan Capital decreased their FY2024 earnings per share estimates for shares of ProQR Therapeutics in a report released on Sunday, November 10th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will earn ($0.31)November 13, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00HC Wainwright raised their target price on ProQR Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday.November 8, 2024 | marketbeat.comProQR Therapeutics price target raised to $10 from $5 at H.C. WainwrightNovember 8, 2024 | tipranks.comProQR Announces Third Quarter 2024 Operating and Financial ResultsNovember 8, 2024 | markets.businessinsider.comProQR Therapeutics reports Q3 EPS (EUR 0.10) vs. (EUR 0.07) last yearNovember 7, 2024 | markets.businessinsider.comProQR Therapeutics Shows Revenue Growth Amid Financial ChallengesNovember 7, 2024 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above Fifty Day Moving Average - Here's WhyProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?November 6, 2024 | marketbeat.comRaymond James Upgrades ProQR Therapeutics N.V. (PRQR)October 29, 2024 | msn.comProQR Therapeutics (NASDAQ:PRQR) Upgraded to Strong-Buy at Raymond JamesRaymond James upgraded ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their target price for the stock from $6.00 to $14.00 in a research report on Tuesday.October 29, 2024 | marketbeat.comProQR Announces Closing of Underwritten Public Offering and Concurrent Private PlacementOctober 25, 2024 | globenewswire.comProQR Therapeutics 18M share Spot Secondary priced at $3.50October 24, 2024 | markets.businessinsider.comProQR Therapeutics announces ordinary shares offering, no amount givenOctober 23, 2024 | markets.businessinsider.comProQR Prices $75 Million Underwritten Public Offering and Concurrent Private PlacementOctober 22, 2024 | globenewswire.comProQR Announces Proposed Underwritten Public Offering of Ordinary SharesOctober 22, 2024 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 yearOctober 21, 2024 | finance.yahoo.comProQR Therapeutics (NASDAQ:PRQR) Stock Quotes, Forecast and News SummaryOctober 17, 2024 | benzinga.comProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics SocietyOctober 7, 2024 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average - Here's WhyProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below 200 Day Moving Average - Here's WhyOctober 5, 2024 | marketbeat.comAutolus Therapeutics plc (6A3A.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | globenewswire.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50-Day Moving Average of $1.90September 10, 2024 | marketbeat.comPRQR ProQR Therapeutics N.V.September 4, 2024 | seekingalpha.comProQR Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 12, 2024 | finance.yahoo.comBuy Rating Affirmed: ProQR’s Promising RNA-Editing Clinical and Preclinical ProspectsAugust 9, 2024 | markets.businessinsider.comProQR GAAP EPS of -€0.03, revenue of €6.31MAugust 8, 2024 | msn.comProQR Announces Second Quarter 2024 Operating and Financial ResultsAugust 8, 2024 | markets.businessinsider.comProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $2.01ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 200 Day Moving Average of $2.01July 18, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Short Interest UpdateProQR Therapeutics (NASDAQ:PRQR - Get Free Report) was the target of a large decrease in short interest during the month of June. As of June 15th, there was short interest totalling 196,600 shares, a decrease of 18.5% from the May 31st total of 241,200 shares. Based on an average daily trading volume, of 124,600 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.4% of the company's stock are short sold.June 29, 2024 | marketbeat.comStockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to "Hold"StockNews.com upgraded shares of ProQR Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday.June 29, 2024 | marketbeat.comStockNews.com Lowers ProQR Therapeutics (NASDAQ:PRQR) to SellStockNews.com downgraded ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Friday.June 21, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Raised to "Hold" at StockNews.comStockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday.June 13, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Rating Lowered to Sell at StockNews.comStockNews.com downgraded shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday.June 5, 2024 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above 50 Day Moving Average of $2.02ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Above 50-Day Moving Average of $2.02June 5, 2024 | marketbeat.com Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. PRQR Media Mentions By Week PRQR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼0.130.60▲Average Medical News Sentiment PRQR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼31▲PRQR Articles Average Week Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Anavex Life Sciences News Today Immunome News Today Kura Oncology News Today Keros Therapeutics News Today Tyra Biosciences News Today Erasca News Today Cronos Group News Today Evolus News Today Dianthus Therapeutics News Today Rapport Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRQR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
